Table 1.
Patient and baseline tumor characteristics
| Characteristic | N (%) |
|---|---|
| Age, ≤45 years | 152 (56.9) |
| Menopausal status | |
| Premenopausal | 163 (61.0) |
| Postmenopausal | 104 (39.0) |
| Stage | |
| 2 | 113 (42.3) |
| 3 | 154 (57.7) |
| Tumor size (cm) | |
| ≤2.0 | 49 (18.4) |
| >2.0 | 118 (81.6) |
| Clinical nodal status | |
| Negative | 73 (27.3) |
| Positive | 194 (72.7) |
| Nuclear grade | |
| 1 | 22 (8.2) |
| 2 | 65 (24.4) |
| 3 | 180 (67.4) |
| HR status | |
| Negative | 104 (39.0) |
| Positive (>1%) | 163 (61.0) |
| HER2 status | |
| Positive | 129 (48.3) |
| Negative | 138 (51.7) |
| Ki-67 index | |
| ≤14% | 58 (21.7) |
| >14% | 209 (78.3) |
| Histology | |
| Invasive ductal carcinoma | 254 (95.1) |
| Others | 13 (4.9) |
| NAC regimens | |
| FEC | 107 (40.1) |
| TEC | 72 (27.0) |
| AT | 30 (11.2) |
| AC followed by T | 58 (21.7) |
| Clinical response | |
| CR | 38 (14.2) |
| PR | 197 (73.8) |
| SD/PD | 32 (12.0) |
NAC, neoadjuvant chemotherapy; HR, hormone receptor; HER-2, human epidermal receptor; FEC, 5-fluorouracil + epirubicin + cyclophosphamide; TEC, docetaxel + epirubicin + cyclophosphamide; AT, doxorubicin + docetaxel; AC followed by T, doxorubicin + cyclophosphamide followed by docetaxel; CR, complete response; PR, partial response; SD/PD, stable disease or progression of disease.